NIOX VERO. NIOX VERO device call-to-action. Order NIOX VERO. Contact us today to order your FeNO by NIOX device and other consumables. Order Now. Services and Markets Act (Financial Promotion) Order (as that shares in Aerocrine can be sold at a price acceptable to. The total value of the Offer, based on ,, shares in Aerocrine, amounts to SEK 1,,,[1] The Offer Price corresponds to a.

Author: Zulukazahn Taujind
Country: Guinea-Bissau
Language: English (Spanish)
Genre: Love
Published (Last): 14 July 2006
Pages: 339
PDF File Size: 14.63 Mb
ePub File Size: 16.37 Mb
ISBN: 241-4-54505-210-9
Downloads: 44191
Price: Free* [*Free Regsitration Required]
Uploader: Miramar

The Extraordinary General Meeting is planned to be held on 7 January In total, subscription undertakings and underwriting commitments correspond aerocrinr more than 75 percent of the full rights issue amount under certain conditions. In addition, the company will leverage the VERO product and software platform to finalize development of a home-treatment monitoring device in accordance with the recently published guidelines for home medical devices by the FDA.

Statement by the Board of Directors of Aerocrine in relation to Circassia’s public cash offer

This will allow the company to realize its growth plans and reach profitability, and thereby create additional shareholder value. Subject to the approval of the rights issue by an Extraordinary General Meeting, the subscription period will run from 14 January up to aerocrinf including 28 January Background and reasons Aerocrine has, untilfocused extensively on research, product development and preparations for the future pricse of the commercial operations.

Since the end ofAerocrine has been undergoing a transition resulting in an increased corporate focus on sales and marketing execution, and the company has invested intensively in preparing and growing its US market presence. In order to further strengthen the position for growth in the US market, the company thoroughly reviewed its US commercial organization during and changes were made to the selling model, including aeorcrine targeting and messaging, introduction of a device evaluation program, and multiple pricing options.

Aerocrine AB B (XSTO:AERO B) – Share price – Chart | AJ Bell Youinvest

Upon implementation aerocrnie these changes, sales initially slowed during the first half of but rebounded in the last half of the second quarter and showed solid growth in the third quarter. Other geographic markets are also showing healthy growth. Looking forward, Aerocrine is on a trend to achieve record sales for the full year This growth is expected to be achieved while the company is continuing to focus on overall expense control and selectively pursue earocrine opportunities with targeted funding.


However, based on current forecasts, and absent a strategic collaboration or larger than expected growth in revenue, existing cash is sufficient to finance the current scope of operations until approximately the end of the second quarter ; and sufficient cash to meet the conditions of the credit agreement at least until the end of December Proceeds from serocrine rights offering will be used to invest in four strategic growth pillars and enable the company to achieve several very valuable inflection points such as: Based on the proposed rights issue, and assuming it will be fully subscribed, liquidity is expected to qnd sufficient to continue the planned operations and attain positive cash flow without additional financing.

AEROCRINE AB strengthens its financial position by a rights issue of approximately SEK 445 million

The subscription price is SEK 0. Shareholders in Aerocrine will have preferential rights to subscribe for new shares in proportion to their holdings.

Each existing share will entitle to seven 7 subscription rights. Two 2 subscription rights will entitle to subscription for one 1 new share. The subscription period subscription through payment will run from 14 January up to and including 28 Januaryor such later date as decided by the Board of Directors.

Trading in subscription rights is expected to take place from 14 January up to and including 26 January The decision on the rights issue is subject to approval by an Extraordinary General Meeting that is planned to take place on Wednesday 7 January Notice of the Extraordinary General Meeting will be published through a separate press release on or about 2 December A prospectus relating to the rights issue will snd made public before the commencement of the subscription period.

  ISO 19338 PDF

No underwriting fee has been requested by or paid to the underwriters. Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases.

Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma.

Aerocrine is based in Sweden with subsidiaries in the U.

abd Aerocrine shares were listed on the Stockholm Stock Exchange in The information was submitted for publication at CET on November 28, Important information The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Aerocrine. Any invitation to the persons concerned to subscribe for shares in Aerocrine will only be made through the prospectus that Aerocrine estimates to publish on or around 12 January This press release may not be released, published or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, Singapore, South Africa, the United States or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations ordeer other actions in addition to what follows from Swedish law.

Nor may the information in this press release be forwarded, reproduced or disclosed in a manner that contravenes such restrictions or would entail such requirements.

Failure to comply with this instruction may result in a violation of applicable awrocrine laws. Forward-looking statements inherently involve both known and aeorcrine risks and uncertainties as they depend on future events and circumstances.

Forward-looking statements do not guarantee future results or development and the actual outcome could differ materially from. For more information, please contact: